Otsuka Holdings Co., Ltd. (OTSKY)
OTCMKTS · Delayed Price · Currency is USD
32.80
+0.95 (2.98%)
At close: Mar 4, 2026
Otsuka Holdings Revenue
In the year 2025, Otsuka Holdings had annual revenue of 2.47T JPY with 5.97% growth. Otsuka Holdings had revenue of 650.15B in the quarter ending December 31, 2025, with 8.40% growth.
Revenue
2.47T JPY
Revenue Growth
+5.97%
P/S Ratio
2.17
Revenue / Employee
71.80M JPY
Employees
34,388
Market Cap
34.19B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.47T | 139.03B | 5.97% |
| Dec 31, 2024 | 2.33T | 311.29B | 15.42% |
| Dec 31, 2023 | 2.02T | 280.57B | 16.14% |
| Dec 31, 2022 | 1.74T | 239.72B | 16.00% |
| Dec 31, 2021 | 1.50T | 75.45B | 5.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 140.12M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
| Northwest Biotherapeutics | 937.00K |
Otsuka Holdings News
- 13 days ago - Otsuka Holdings Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 13 days ago - Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 15 days ago - Full Year 2025 Otsuka Holdings Co Ltd Earnings Presentation Transcript - GuruFocus
- 20 days ago - Otsuka Holdings FY25 Profit Rises, Sees Weak Profit In H1, FY26 - Nasdaq
- 3 months ago - US FDA approves Otsuka's kidney disease drug - Reuters
- 5 months ago - Shares of Asian drugmakers drop after Trump threatens tariffs - Reuters
- 7 months ago - Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Otsuka Holdings Co., Ltd. (OTSKY) Q2 FY2024 Earnings Call Transcript - Seeking Alpha